Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Refractory hypoglycemia is sensitive to octreotide therapy: is it triggered by sorafenib or hepatocellular carcinoma?
Anticancer Drugs
December 2024
Department of Medical Oncology.
Hypoglycemia is a medical emergency with a multitude of potential causes. Paraneoplastic hypoglycemia represents a rare cause of this condition. Hepatocellular carcinoma (HCC) can result in paraneoplastic hypoglycemia through extensive tumor infiltration and the presence of insulin-like growth factor 2 precursors.
View Article and Find Full Text PDF[Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.
Lancet
June 2024
Endocrinology, IRCCS Policlinico San Martino and DiMI, University of Genova, Genoa, Italy.
Article Synopsis
- There are no established first-line treatments for higher grade gastroenteropancreatic neuroendocrine tumors (NETs), prompting a study on the effectiveness of Lu-DOTA-TATE (Lu-Dotatate) as a potential option.
- The NETTER-2 trial was a phase 3 study that randomized patients with advanced NETs to receive either Lu-Dotatate plus octreotide or high-dose octreotide alone, focusing on progression-free survival as the main outcome.
- Results showed that patients receiving Lu-Dotatate had a significantly longer median progression-free survival of 22.8 months compared to 8.5 months for those on high-dose octreotide, indicating Lu-Dotatate may
Lutetium [Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study.
Eur J Nucl Med Mol Imaging
September 2024
Nuclear Medicine Unit, IRCCS-Fondazione Istituto Nazionale dei Tumori, Milan, Italy.
Purpose: Gastroenteropancreatic -neuroendocrine tumours (GEP-NETs) are commonly treated with surgical resection or long-term therapies for tumour growth control. Lutetium [Lu]-DOTA-TATE was approved for the treatment of GEP-NETs after the phase III NETTER 1trial demonstrated improved progression free survival, objective response rates and health-related quality of life (HRQoL) compared to high-dose somatostatin analogues. No real-world data exist on prescribing habits and clinically significant endpoints for [Lu]Lu-DOTA-TATE treatment in Italy.
View Article and Find Full Text PDFHypertensive Crisis in a Patient With a Functioning Mesenteric Paraganglioma: Dramatic Response to Octreotide Treatment.
AACE Clin Case Rep
May 2023
Department of Endocrinology, Sultan Qaboos Comprehensive Cancer Care and Research Centre (SQCCCRC), Muscat, Sultanate of Oman.
Background/objective: To report a dramatic and immediate clinical and biochemical response during treatment with octreotide in a patient with a functioning mesenteric paraganglioma (PGL).
Case Report: A 44-year-old woman was admitted with a severe hypertensive crisis and a blood pressure reaching 260/150 mm Hg. She was 2 months postpartum and had been previously diagnosed with pre-eclampsia.
Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story.
J Endocrinol Invest
January 2024
Endocrinology Unit, Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant'Andrea Hospital, ENETS Center of Excellence, Via di Grottarossa 1038, 00189, Rome, Italy.
Purpose: The specific indications of somatostatin analogs (SSAs) in patients with neuroendocrine tumor (NET) emerged over the time. The objective of this review is to summarize and discuss the most relevant data concerning long-acting SSAs in NET.
Methods: A narrative review was performed including publications focusing on therapy with the long-acting octreotide, lanreotide, and pasireotide in patients with NET.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!